Sarepta Therapeutics (SRPT) Reports Publication of Encouraging Phase I Data for Ebola and Marburg Virus Drug Candidates
Tweet Send to a Friend
Sarepta Therapeutics (NASDAQ: SRPT) announced the publication of results from two single ascending-dose studies that demonstrated no clinical or toxicologic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
